百花医药或易主，控股股东买入股份一年浮盈4亿多元

Core Viewpoint - Baihua Pharmaceutical (600721) announced a suspension of trading due to its controlling shareholders planning a share transfer that may lead to a change in control [1] Group 1: Share Transfer Announcement - The controlling shareholders, Mi Zaiqi, Mi Enhua, and Yang Xiaoling, are negotiating a share transfer that could change the company's control [1] - Trading of Baihua Pharmaceutical's stock will be suspended starting December 29, 2025, for no more than two trading days [1] - As of the last trading day, the stock price was 12.24 CNY per share, with a market capitalization of 4.707 billion CNY [1] Group 2: Historical Context and Financials - One year ago, the same shareholders acquired shares through a transfer, with a total of 79.53 million shares (20.71% of total shares) being transferred at a price of 6.8 CNY per share, totaling 541 million CNY [2] - The current share price represents an 80% increase from the previous transfer price, resulting in an unrealized gain of approximately 430 million CNY for the shareholders [2] - The company reported a revenue of 298.6 million CNY for the first three quarters of 2025, a year-on-year increase of 2.74%, and a net profit of 32.67 million CNY, up 36.41% year-on-year [3] Group 3: Business Model - Baihua Pharmaceutical's business model focuses on providing integrated services in drug discovery, clinical trials, and regulatory submissions, catering to diverse and personalized technical requirements of clients [3]